Finance

$5.8 Million has been invested in the company to date. Seeking a minimum of $5 million and up to $30M at an estimated ~$50 million pre-money valuation. Funds will be used to bring the first products to market.

 

Ownership

Company is 60% owned by founders/management. Remaining by a diverse group of shareholders

 

Exit timeline. Liquidity outlook​​

Company via an exit through the sale of the firm to a large pharma company or through an IPO, the occurrence of which is anticipated by 2019.

 

X Factor

We have a 10 x on the company at the current valuation if successful.